Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline
Alzheimer's disease is a heterogeneous disorder. Understanding the biological basis for this heterogeneity is key for developing personalized medicine. We identified atrophy subtypes in Alzheimer's disease dementia and tested whether these subtypes are already present in prodromal Alzheime...
Gespeichert in:
| Veröffentlicht in: | Brain (London, England : 1878) Jg. 141; H. 12; S. 3443 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
01.12.2018
|
| ISSN: | 1460-2156, 1460-2156 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Alzheimer's disease is a heterogeneous disorder. Understanding the biological basis for this heterogeneity is key for developing personalized medicine. We identified atrophy subtypes in Alzheimer's disease dementia and tested whether these subtypes are already present in prodromal Alzheimer's disease and could explain interindividual differences in cognitive decline. First we retrospectively identified atrophy subtypes from structural MRI with a data-driven cluster analysis in three datasets of patients with Alzheimer's disease dementia: discovery data (dataset 1: n = 299, age = 67 ± 8, 50% female), and two independent external validation datasets (dataset 2: n = 181, age = 66 ± 7, 52% female; dataset 3: n = 227, age = 74 ± 8, 44% female). Subtypes were compared on clinical, cognitive and biological characteristics. Next, we classified prodromal Alzheimer's disease participants (n = 603, age = 72 ± 8, 43% female) according to the best matching subtype to their atrophy pattern, and we tested whether subtypes showed cognitive decline in specific domains. In all Alzheimer's disease dementia datasets we consistently identified four atrophy subtypes: (i) medial-temporal predominant atrophy with worst memory and language function, older age, lowest CSF tau levels and highest amount of vascular lesions; (ii) parieto-occipital atrophy with poor executive/attention and visuospatial functioning and high CSF tau; (iii) mild atrophy with best cognitive performance, young age, but highest CSF tau levels; and (iv) diffuse cortical atrophy with intermediate clinical, cognitive and biological features. Prodromal Alzheimer's disease participants classified into one of these subtypes showed similar subtype characteristics at baseline as Alzheimer's disease dementia subtypes. Compared across subtypes in prodromal Alzheimer's disease, the medial-temporal subtype showed fastest decline in memory and language over time; the parieto-occipital subtype declined fastest on executive/attention domain; the diffuse subtype in visuospatial functioning; and the mild subtype showed intermediate decline in all domains. Robust atrophy subtypes exist in Alzheimer's disease with distinct clinical and biological disease expression. Here we observe that these subtypes can already be detected in prodromal Alzheimer's disease, and that these may inform on expected trajectories of cognitive decline. |
|---|---|
| AbstractList | Alzheimer's disease is a heterogeneous disorder. Understanding the biological basis for this heterogeneity is key for developing personalized medicine. We identified atrophy subtypes in Alzheimer's disease dementia and tested whether these subtypes are already present in prodromal Alzheimer's disease and could explain interindividual differences in cognitive decline. First we retrospectively identified atrophy subtypes from structural MRI with a data-driven cluster analysis in three datasets of patients with Alzheimer's disease dementia: discovery data (dataset 1: n = 299, age = 67 ± 8, 50% female), and two independent external validation datasets (dataset 2: n = 181, age = 66 ± 7, 52% female; dataset 3: n = 227, age = 74 ± 8, 44% female). Subtypes were compared on clinical, cognitive and biological characteristics. Next, we classified prodromal Alzheimer's disease participants (n = 603, age = 72 ± 8, 43% female) according to the best matching subtype to their atrophy pattern, and we tested whether subtypes showed cognitive decline in specific domains. In all Alzheimer's disease dementia datasets we consistently identified four atrophy subtypes: (i) medial-temporal predominant atrophy with worst memory and language function, older age, lowest CSF tau levels and highest amount of vascular lesions; (ii) parieto-occipital atrophy with poor executive/attention and visuospatial functioning and high CSF tau; (iii) mild atrophy with best cognitive performance, young age, but highest CSF tau levels; and (iv) diffuse cortical atrophy with intermediate clinical, cognitive and biological features. Prodromal Alzheimer's disease participants classified into one of these subtypes showed similar subtype characteristics at baseline as Alzheimer's disease dementia subtypes. Compared across subtypes in prodromal Alzheimer's disease, the medial-temporal subtype showed fastest decline in memory and language over time; the parieto-occipital subtype declined fastest on executive/attention domain; the diffuse subtype in visuospatial functioning; and the mild subtype showed intermediate decline in all domains. Robust atrophy subtypes exist in Alzheimer's disease with distinct clinical and biological disease expression. Here we observe that these subtypes can already be detected in prodromal Alzheimer's disease, and that these may inform on expected trajectories of cognitive decline.Alzheimer's disease is a heterogeneous disorder. Understanding the biological basis for this heterogeneity is key for developing personalized medicine. We identified atrophy subtypes in Alzheimer's disease dementia and tested whether these subtypes are already present in prodromal Alzheimer's disease and could explain interindividual differences in cognitive decline. First we retrospectively identified atrophy subtypes from structural MRI with a data-driven cluster analysis in three datasets of patients with Alzheimer's disease dementia: discovery data (dataset 1: n = 299, age = 67 ± 8, 50% female), and two independent external validation datasets (dataset 2: n = 181, age = 66 ± 7, 52% female; dataset 3: n = 227, age = 74 ± 8, 44% female). Subtypes were compared on clinical, cognitive and biological characteristics. Next, we classified prodromal Alzheimer's disease participants (n = 603, age = 72 ± 8, 43% female) according to the best matching subtype to their atrophy pattern, and we tested whether subtypes showed cognitive decline in specific domains. In all Alzheimer's disease dementia datasets we consistently identified four atrophy subtypes: (i) medial-temporal predominant atrophy with worst memory and language function, older age, lowest CSF tau levels and highest amount of vascular lesions; (ii) parieto-occipital atrophy with poor executive/attention and visuospatial functioning and high CSF tau; (iii) mild atrophy with best cognitive performance, young age, but highest CSF tau levels; and (iv) diffuse cortical atrophy with intermediate clinical, cognitive and biological features. Prodromal Alzheimer's disease participants classified into one of these subtypes showed similar subtype characteristics at baseline as Alzheimer's disease dementia subtypes. Compared across subtypes in prodromal Alzheimer's disease, the medial-temporal subtype showed fastest decline in memory and language over time; the parieto-occipital subtype declined fastest on executive/attention domain; the diffuse subtype in visuospatial functioning; and the mild subtype showed intermediate decline in all domains. Robust atrophy subtypes exist in Alzheimer's disease with distinct clinical and biological disease expression. Here we observe that these subtypes can already be detected in prodromal Alzheimer's disease, and that these may inform on expected trajectories of cognitive decline. Alzheimer's disease is a heterogeneous disorder. Understanding the biological basis for this heterogeneity is key for developing personalized medicine. We identified atrophy subtypes in Alzheimer's disease dementia and tested whether these subtypes are already present in prodromal Alzheimer's disease and could explain interindividual differences in cognitive decline. First we retrospectively identified atrophy subtypes from structural MRI with a data-driven cluster analysis in three datasets of patients with Alzheimer's disease dementia: discovery data (dataset 1: n = 299, age = 67 ± 8, 50% female), and two independent external validation datasets (dataset 2: n = 181, age = 66 ± 7, 52% female; dataset 3: n = 227, age = 74 ± 8, 44% female). Subtypes were compared on clinical, cognitive and biological characteristics. Next, we classified prodromal Alzheimer's disease participants (n = 603, age = 72 ± 8, 43% female) according to the best matching subtype to their atrophy pattern, and we tested whether subtypes showed cognitive decline in specific domains. In all Alzheimer's disease dementia datasets we consistently identified four atrophy subtypes: (i) medial-temporal predominant atrophy with worst memory and language function, older age, lowest CSF tau levels and highest amount of vascular lesions; (ii) parieto-occipital atrophy with poor executive/attention and visuospatial functioning and high CSF tau; (iii) mild atrophy with best cognitive performance, young age, but highest CSF tau levels; and (iv) diffuse cortical atrophy with intermediate clinical, cognitive and biological features. Prodromal Alzheimer's disease participants classified into one of these subtypes showed similar subtype characteristics at baseline as Alzheimer's disease dementia subtypes. Compared across subtypes in prodromal Alzheimer's disease, the medial-temporal subtype showed fastest decline in memory and language over time; the parieto-occipital subtype declined fastest on executive/attention domain; the diffuse subtype in visuospatial functioning; and the mild subtype showed intermediate decline in all domains. Robust atrophy subtypes exist in Alzheimer's disease with distinct clinical and biological disease expression. Here we observe that these subtypes can already be detected in prodromal Alzheimer's disease, and that these may inform on expected trajectories of cognitive decline. |
| Author | Tijms, Betty M Visser, Pieter Jelle Dicks, Ellen van der Flier, Wiesje M Teunissen, Charlotte E Barkhof, Frederik Ten Kate, Mara Scheltens, Philip |
| Author_xml | – sequence: 1 givenname: Mara surname: Ten Kate fullname: Ten Kate, Mara organization: Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands – sequence: 2 givenname: Ellen surname: Dicks fullname: Dicks, Ellen organization: Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands – sequence: 3 givenname: Pieter Jelle surname: Visser fullname: Visser, Pieter Jelle organization: Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands – sequence: 4 givenname: Wiesje M surname: van der Flier fullname: van der Flier, Wiesje M organization: Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands – sequence: 5 givenname: Charlotte E surname: Teunissen fullname: Teunissen, Charlotte E organization: Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, VU University Medical Center, Neuroscience Amsterdam, The Netherlands – sequence: 6 givenname: Frederik surname: Barkhof fullname: Barkhof, Frederik organization: Institutes of Neurology and Healthcare Engineering, University College London, London, UK – sequence: 7 givenname: Philip surname: Scheltens fullname: Scheltens, Philip organization: Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands – sequence: 8 givenname: Betty M surname: Tijms fullname: Tijms, Betty M organization: Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30351346$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkMtLAzEYxINU7ENvniU3vaxNNt_G7rGU-oCCF8Xjkse3NrIvk6xl_etdsIKHYebwYxhmTiZN2yAhl5zdcpaLpfbKNUt1GFIJJ2TGQbIk5Zmc_MtTMg_hgzEOIpVnZCqYyLgAOSNv6-jbbj_Q0Os4dBioa2jnW-vbWlV0XX3v0dXorwO1LqAKSJUfFUJrnIpo6cHFPTXte-Oi-0Jq0VSuwXNyWqoq4MXRF-T1fvuyeUx2zw9Pm_UuMcBlTJQu9V0qEfJcaJBcaAkqNzlapq2GjJdGAoyQzKxZgcRslQGDUpQMmBY6XZCb395x82ePIRa1CwarSjXY9qFIOXAmVjznI3p1RHtdoy0672rlh-LvjPQH6cpkjw |
| CitedBy_id | crossref_primary_10_1186_s13195_021_00847_y crossref_primary_10_1016_j_jalz_2019_08_201 crossref_primary_10_1016_j_dscb_2021_100005 crossref_primary_10_1038_s41398_024_03220_3 crossref_primary_10_3389_fnagi_2020_581767 crossref_primary_10_3390_biomedicines11072035 crossref_primary_10_1371_journal_pone_0292527 crossref_primary_10_3389_fncom_2023_1243092 crossref_primary_10_3233_JAD_210719 crossref_primary_10_1016_j_brain_2024_100093 crossref_primary_10_1093_brain_awy282 crossref_primary_10_1177_13872877251371734 crossref_primary_10_1093_cercor_bhab130 crossref_primary_10_3233_JAD_231149 crossref_primary_10_1212_WNL_0000000000010498 crossref_primary_10_3390_brainsci12020187 crossref_primary_10_1016_j_media_2021_102304 crossref_primary_10_1140_epjs_s11734_023_00777_w crossref_primary_10_3389_fnagi_2021_599724 crossref_primary_10_1038_s41598_025_98338_9 crossref_primary_10_1093_brain_awaa325 crossref_primary_10_1002_acn3_50948 crossref_primary_10_1016_j_neuroimage_2024_120737 crossref_primary_10_1016_j_neuron_2025_04_010 crossref_primary_10_3389_fcell_2021_704298 crossref_primary_10_1002_hbm_25414 crossref_primary_10_3389_fnagi_2024_1328301 crossref_primary_10_1016_j_csbj_2025_04_007 crossref_primary_10_1016_j_neubiorev_2023_105169 crossref_primary_10_3233_JAD_230548 crossref_primary_10_1002_hbm_26146 crossref_primary_10_1016_S0140_6736_25_01329_7 crossref_primary_10_1016_j_neuroimage_2025_121381 crossref_primary_10_3233_JAD_201068 crossref_primary_10_3389_fnins_2024_1355695 crossref_primary_10_1002_dad2_12135 crossref_primary_10_1038_s41531_024_00759_2 crossref_primary_10_1093_brain_awae118 crossref_primary_10_1016_j_biopsych_2020_01_016 crossref_primary_10_3389_fnagi_2023_1267434 crossref_primary_10_1002_alz_14174 crossref_primary_10_1038_s41467_023_44271_2 crossref_primary_10_1136_jnnp_2021_326611 crossref_primary_10_1016_j_biopsych_2024_12_009 crossref_primary_10_1111_ene_14639 crossref_primary_10_1002_acn3_51539 crossref_primary_10_1002_alz_12717 crossref_primary_10_1093_brain_awz384 crossref_primary_10_3233_JAD_220249 crossref_primary_10_1001_jamanetworkopen_2022_7512 crossref_primary_10_1016_j_nicl_2021_102660 crossref_primary_10_1515_revneuro_2023_0033 crossref_primary_10_1038_s12276_024_01218_x crossref_primary_10_1016_j_nbd_2021_105558 crossref_primary_10_1212_WNL_0000000000010629 crossref_primary_10_1016_j_pnpbp_2023_110873 crossref_primary_10_1038_s41583_023_00779_6 crossref_primary_10_1038_s41467_021_26703_z crossref_primary_10_1097_CM9_0000000000002851 crossref_primary_10_1002_alz_13069 crossref_primary_10_1186_s12911_021_01693_6 crossref_primary_10_3389_fnins_2021_731292 crossref_primary_10_1016_j_inpsyc_2025_100105 crossref_primary_10_1038_s41598_023_37569_0 crossref_primary_10_1051_e3sconf_202125302095 crossref_primary_10_12998_wjcc_v10_i2_448 crossref_primary_10_3389_fnagi_2019_00294 crossref_primary_10_3390_ijms241814177 crossref_primary_10_1016_j_nicl_2019_101771 crossref_primary_10_1016_j_neuint_2020_104853 crossref_primary_10_3389_fdata_2021_676168 crossref_primary_10_1016_j_brainres_2023_148675 crossref_primary_10_1038_s41591_024_03144_x crossref_primary_10_1007_s40520_023_02456_1 crossref_primary_10_1007_s00415_024_12281_9 crossref_primary_10_3233_JAD_220825 crossref_primary_10_3390_brainsci11020278 crossref_primary_10_1001_jamanetworkopen_2023_18153 crossref_primary_10_3390_ijms222011185 crossref_primary_10_1016_j_phrs_2023_107038 crossref_primary_10_1186_s13195_025_01753_3 crossref_primary_10_1007_s11682_022_00678_x crossref_primary_10_1111_ejn_15854 crossref_primary_10_3389_fphys_2025_1606267 crossref_primary_10_1016_j_neurobiolaging_2019_03_006 crossref_primary_10_1089_neu_2022_0365 crossref_primary_10_1002_alz_12231 crossref_primary_10_1097_WCO_0000000000001177 crossref_primary_10_1002_alz_14096 crossref_primary_10_1093_brain_awab165 crossref_primary_10_1186_s13195_023_01192_y crossref_primary_10_1007_s11011_025_01587_w crossref_primary_10_3233_JAD_201274 crossref_primary_10_1016_j_neurobiolaging_2019_08_032 crossref_primary_10_1016_j_biopsych_2022_06_019 crossref_primary_10_1080_10408363_2019_1670613 crossref_primary_10_1016_j_nbd_2024_106473 crossref_primary_10_1016_j_neuroscience_2023_01_019 crossref_primary_10_1007_s11682_019_00176_7 crossref_primary_10_1016_j_compbiomed_2024_109190 crossref_primary_10_3233_JAD_210533 crossref_primary_10_1186_s13195_021_00785_9 crossref_primary_10_1212_WNL_0000000000207298 |
| ContentType | Journal Article |
| CorporateAuthor | Alzheimer’s Disease Neuroimaging Initiative |
| CorporateAuthor_xml | – name: Alzheimer’s Disease Neuroimaging Initiative |
| DBID | NPM 7X8 |
| DOI | 10.1093/brain/awy264 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2156 |
| ExternalDocumentID | 30351346 |
| Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: CIHR – fundername: NIA NIH HHS grantid: U01 AG024904 |
| GroupedDBID | --- -E4 -~X .2P .I3 .XZ .ZR 0R~ 1TH 23N 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6PF 70D AABZA AACZT AAIMJ AAJKP AAJQQ AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAVLN AAWTL ABDFA ABEJV ABEUO ABGNP ABIVO ABIXL ABJNI ABKDP ABLJU ABMNT ABNHQ ABNKS ABPQP ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABXZS ABZBJ ACGFS ACIWK ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AELWJ AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFGWE AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIJHB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ARIXL ATGXG AXUDD AYOIW BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BR6 BSWAC BTRTY BVRKM C45 CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EMOBN ENERS F5P F9B FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M49 MHKGH ML0 N9A NGC NLBLG NOMLY NOYVH NPM NU- O9- OAUYM OAWHX OBOKY OCZFY ODMLO OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX ROZ RUSNO RW1 RXO TCURE TEORI TJX TLC TR2 VVN W8F WH7 WOQ X7H YAYTL YKOAZ YSK YXANX ZKX ~91 7X8 ABUFD AJBYB |
| ID | FETCH-LOGICAL-c416t-abfb726e4993b4613b64a9c9ed0bdb451fc644bfb65dc846e585404f3f040b3b2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 112 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000456597100019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1460-2156 |
| IngestDate | Sun Nov 09 11:09:00 EST 2025 Thu Apr 03 07:02:53 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c416t-abfb726e4993b4613b64a9c9ed0bdb451fc644bfb65dc846e585404f3f040b3b2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://academic.oup.com/brain/article-pdf/141/12/3443/29154038/awy264.pdf |
| PMID | 30351346 |
| PQID | 2141038191 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2141038191 pubmed_primary_30351346 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-12-01 |
| PublicationDateYYYYMMDD | 2018-12-01 |
| PublicationDate_xml | – month: 12 year: 2018 text: 2018-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Brain (London, England : 1878) |
| PublicationTitleAlternate | Brain |
| PublicationYear | 2018 |
| References | 30496363 - Brain. 2018 Dec 1;141(12):3285-3287 |
| References_xml | – reference: 30496363 - Brain. 2018 Dec 1;141(12):3285-3287 |
| SSID | ssj0014326 |
| Score | 2.5944426 |
| Snippet | Alzheimer's disease is a heterogeneous disorder. Understanding the biological basis for this heterogeneity is key for developing personalized medicine. We... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 3443 |
| Title | Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30351346 https://www.proquest.com/docview/2141038191 |
| Volume | 141 |
| WOSCitedRecordID | wos000456597100019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4ftQXEQRPodts9nWSIooHW3rw0VtJNgkW7G7dbRX99c7spvYkCB52TxsIs_P4Zr5JhpALKULNVSyZlgFnQkrJpBdrpjzrhSa1RlRD-57uo14vHgySviu4la6tcu4TK0et8xRr5C2ODYlVenE1eWM4NQrZVTdCY5k0fIAyaJjRYMEiCJ-700Ueg9AWusZ3SOJbCgcwtOTHJ8e7Bn4Dl1WQud387_a2yIaDl7RT68M2WTLZDlnrOgJ9lzx3pkUOkqXlTGH1taSjjKITLfIxrnv9ejGjsSkuS-qoGyoLeNxPNJpi4Zb-NB1RbfBspdkjj7c3D9d3zM1WYClAsCmTyqqIhwYSHl8JiOkqFDJJE6M9pZUI2jYFpAQfhYFOAaMYSCuEJ6xvweqVr_g-WcnyzBwSqoUCFGJtAEgBrw9Ubc4hCdMqQm-a-E1yPhfZEHQXCQmZmXxWDhdCa5KDWu7DSX3JxtBHitMX4dEfVh-TdcAxcd1lckIaFizXnJLV9H06KouzSing3et3vwFsMcNv |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Atrophy+subtypes+in+prodromal+Alzheimer%27s+disease+are+associated+with+cognitive+decline&rft.jtitle=Brain+%28London%2C+England+%3A+1878%29&rft.au=Ten+Kate%2C+Mara&rft.au=Dicks%2C+Ellen&rft.au=Visser%2C+Pieter+Jelle&rft.au=van+der+Flier%2C+Wiesje+M&rft.date=2018-12-01&rft.eissn=1460-2156&rft.volume=141&rft.issue=12&rft.spage=3443&rft_id=info:doi/10.1093%2Fbrain%2Fawy264&rft_id=info%3Apmid%2F30351346&rft_id=info%3Apmid%2F30351346&rft.externalDocID=30351346 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2156&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2156&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2156&client=summon |